Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
VC Playbook: Finding Early-Stage Financing When Money Is Scarce
Early-stage companies need to be more flexible on the financing terms they are willing to accept and in finding ways to gather evidence to support the impact of their products or services.
The New Generation Of Investor: Creating Value From Diamonds In The Rough
Debbie Dumont, co-founder of Bioqube Ventures, and one of In Vivo’s Rising Leaders, talks about the company’s investment model, Europe’s translational challenges, and aligning passion and purpose to find ultimate fulfilment.
Deerfield Management On Fund Building, Philanthropy, And Optimism For The Future
Andrew ElBardissi, partner on Deerfield Management’s medical technologies team, spoke to In Vivo sister publication Medtech Insight about the fund’s investment strategy, the changing face of medtech, and how investment in the life sciences sector will continue to change post-COVID.
European Investor Sentiment Rebounds On Cell And Gene Therapy
Investors at the Advanced Therapies Europe conference in London struck a bullish note on the state of the market and offered up advice for cell and gene developers from fundraising, platform development to manufacturing.
Pushing Forward: Venture Capitalist Priorities To Accelerate European Biotech
Sharing his thoughts on the European funding landscape, the importance of software, and sustainable investments, INKEF Capital’s Thijs Cohen Tervaert talks to In Vivo about his investment priorities.
Bigger Money: Private Equity Grabs European VC
Deals show large investors’ appetite for early-stage biotech, but can VC and PE rub along?
The Biopharma A List: Taking The Pulse Of Newco Creation
The market for new company creation in the biopharma sector remains healthy and poised to continue fostering the establishment of start-ups, based on a new In Vivo study of the strong initial investments that pharma and biotech companies receive.
A Guiding Hand For Biotech Start-Ups In Turbulent Times
Rising Leader Therese Liechtenstein is playing an integral part in the creation and financing of multiple companies in the M Ventures portfolio, guiding them towards key value inflection points that a potential partner or acquirer would like to see.
From Big Pharma To VC: The Road Travelled By Third Rock’s David Kaufman
VC Playbook: Partner at Third Rock Ventures, David Kaufman, talks to In Vivo about the venture capital firm’s company creation strategy and seeking ‘white space’ in biopharma for innovation.
Digital Health Investment In India: Rearing Unicorns
Leaders from HealthQuad, the largest healthtech venture capital fund in India, talk to In Vivo about why the country is a growing and promising market for digital investment.
Experience Counts For VC Success: HealthCap Hits 25 Year Mark
VC Playbook: The fundamentals do not change in life sciences investing – good science, unmet need and social responsibility.
Pfizer Ventures On Striking A Balance Between Strategic And Financial Interests
VC Playbook: Pfizer Ventures senior managing partner Barbara Dalton shares insights into how the corporate venture group balances a dual mandate, the trade-offs needed and what success looks like for a CVC.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.